top of page

Proteometer-UFT Kit 

Proteometer-UFT Kit 

The Proteometer-UFT Kit runs an at-line titer measurement of mAbs in less than 90 seconds. It requires no sample preparation or Protein A and is utilized with a 2-pump liquid chromatograph with a fluorescence detector (1-pump systems are usable with minimal sample prep, no Protein A).

It solves several problems in drug development and clone selection by providing immediate titer from clarified fermentation broth (CFB) and is potentially more accurate than Protein A due to fewer sample manipulation steps.

The product is developed specifically for pharmaceutical scientists, engineers, and production managers to optimize pre- and post-purification testing. It benefits Process R&D by allowing scientists to quickly study the titer range.
 

Kit Components

  • MD Module

  • Standard Tee

  • Buffer Packets 

  • Reagent Packets

  • DMF

  • Instructions for Use

Additional Product Information: 

UFT Chart-updated 513transparent background.png

TESTIMONIALS

Architectural Structure

“Novilytic’s Proteometer is a disruptive breakthrough that finally solves the FDA's requirement to continuously monitor t-mAb proteoforms during fermentation.

 

The approach improves product safety, reduces COPQ and post release testing, and paves the way for real-time product release, reducing inventory costs. 

 

The solution combines novel sample handing and artificial intelligence with proven analytical technology that is easy to deploy and support, and provides near instantaneous ROI.”

Martin Long, BSc.
Performance Validation, Inc. – President & CEO
(Analytical Sciences Business, Brooks Life Sciences, Thermo, Perkin Elmer)

Architectural Structure

"As analytical tools have matured for the quality control and characterization of isolated biopharmaceuticals, the application of advanced analytical systems to dynamically contribute to process monitoring and control in complex bioreactors is critical for enhanced process efficiency and product quality.

 

The Proteometer is expected to play a central role in the development and commercialization of next-level biological manufacturing control strategies. The integration of complementary bioprocess analytical data facilitates decision-making through a powerful link between the manufacturing space and the QC laboratory."

Eugene L. Inman, Ph.D.
Pharmaceutical Quality Consultant
Retired Eli Lilly and Company

bottom of page